| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|
|
Madnezz
Member |
21-Jan-2008 09:25
|
|
x 0
x 0 Alert Admin |
Good, covered all the gap. I would prefer this way rather then big gap up. |
| Useful To Me Not Useful To Me | |
|
XiaoMaGe888
Senior |
21-Jan-2008 09:24
|
|
x 0
x 0 Alert Admin |
Better dun sell,those contra player due on Friday must clear this morning. BIG Cheers!!!!!!!!!!!!!!!!!!! |
| Useful To Me Not Useful To Me | |
|
|
|
|
huatah
Veteran |
21-Jan-2008 09:24
|
|
x 0
x 0 Alert Admin |
indeed.. de halt kindof spolit de wave of Cheonging.. pretty disappointed with the movement.. Let's c if situation improve better... anyway.. me sit back and monitor first.. |
| Useful To Me Not Useful To Me | |
|
superbad2
Member |
21-Jan-2008 09:19
|
|
x 0
x 0 Alert Admin |
Sometimes I wanna smack that stupid BIG ceo.. why halt the whole day? Spoil the mood.. now nobody wanna buy.. KNS. |
| Useful To Me Not Useful To Me | |
|
cashiertan
Elite |
21-Jan-2008 09:18
|
|
x 0
x 0 Alert Admin |
gap covered. |
| Useful To Me Not Useful To Me | |
|
|
|
|
jackjames
Elite |
21-Jan-2008 09:10
|
|
x 0
x 0 Alert Admin |
bengster, u are early today, heee... seems like selling forece is in place now.. anyway, i am going to take 2 days off sitting at home, yawning... |
| Useful To Me Not Useful To Me | |
|
synnexo
Veteran |
21-Jan-2008 09:09
|
|
x 0
x 0 Alert Admin |
Why is it in reverse gear? |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
21-Jan-2008 09:03
|
|
x 0
x 0 Alert Admin |
Stupid sellers. Sell at $1.06??? My guess is it should test $1.22 today |
| Useful To Me Not Useful To Me | |
|
|
|
|
jackjames
Elite |
21-Jan-2008 09:01
|
|
x 0
x 0 Alert Admin |
okay, now the rally starts, kekekekkee... let's see.. |
| Useful To Me Not Useful To Me | |
|
jackjames
Elite |
21-Jan-2008 08:59
|
|
x 0
x 0 Alert Admin |
what???? 1.06 now only?? so cheap?????????????? |
| Useful To Me Not Useful To Me | |
|
novena_33
Veteran |
21-Jan-2008 08:27
|
|
x 0
x 0 Alert Admin |
piss JackJames...... better look at the screen today....who knows...maybe it can break the $1.5 today.................... 
not asking u to buy or sell .............. |
| Useful To Me Not Useful To Me | |
|
idesa168
Elite |
20-Jan-2008 23:30
|
|
x 0
x 0 Alert Admin |
I had closed all positions in stock mkt due to bad sentiment lately on Friday. However I did not managed to liquidate this BIG as it had called for a trading halt on that day. I had added an additional 8 lots @$1.00 on 10 Jan as a bet with Elite P to let it roll for 2 weeks. I think I will sell all my holding and leaving these 8 lots for another few days till it hit 2 weeks to see what's the outcome...lol! Dun be mistaken that I am negative with BIG and I wish to cash out. I am seeing my whole investment as a big picture and there is no point for me to keep these. I will be back to the stock mkt when all dust settle. May I wish all of you huat for the coming months, years, and especially a big thanks to Bengster for providing so much information unselfishly. Like what Warren Buffet had said, you do not need to invest in many counter, just look out for a winner and heavily bet on it will make you a winner like him too. Bengster had demonstrated that. I dun see him posting elsewhere except in this BIG, which make me strongly believe that he had invested in nothing else but the BIG. Bengster, Good luck to you. I will be back...lol! |
| Useful To Me Not Useful To Me | |
|
|
|
|
bengster68
Master |
20-Jan-2008 22:26
|
|
x 0
x 0 Alert Admin |
This was the situation when these DES company/division were bought over by rivals: Conor US$1.4B: CE approved. Patent infringement liability instituted by Angiotech and BSX. Uses paclitaxel drug (toxic and not as effective as a good limus drug like Biolimus, Sirolimus or Everolimus). Costar DES program was totally scrapped by JNJ because it is the worst performing DES. Xience US$4.1B: Not CE approved when bought over by Abbott. No patent assets or patent infringement liability. Durable polymer. Late thrombosis problems. Biosensors (current market cap US$0.7B as at last closing price): Proprietary BiolimusA9 drug and PLA biodegredable polymer stent technology, holding the most important patent in the DES industry now "any limus drug on biodegredable polymer", top class clinical results (with very wide margins of performance superiority). Zero late thrombosis problem because Biomatrix reverts to BMS after 6 months. Finally CE approved. JWMS is now a subsidiary of BIG. Tomorrow's chiong is not only about BIG's CE approval. There is powerful TWIN TURBO chiong as Terumo also got their CE!!! So there will be TWIN TURBO chiong, get it??? I know Xtent and Devax will be next in line to get their CE approval. The CE bar has been raised but BIG's licensees will all get their CE. For the other newer DES players, the barrier of entry now is much higher than before. Previously all the 3 licensees have to depend on BIG (the principal licensee holder to get CE approved) before their's can be approved. BIG's group of licensees represents the new and strongest emerging group of DES players. I am very confident BIG's share price will easily cruise above $1.12 (23/05/07 high) tomorrow. The most challenging part is whether share price can break through the early 2006 resistance level of $1.22. If it breaks through, then we have a strong breakout and next resistance will be $1.50 (the historical high). Tightened you seat belt tomorrow fellow forumers. Don't sell away your winners too early. If possible, hold them until the BIG jackpot of $3. Enjoy the rocket ride tomorrow. BIOSENSORS CHEEEONG ARRGGGHHHH!!!    
|
| Useful To Me Not Useful To Me | |
|
jackjames
Elite |
20-Jan-2008 19:57
|
|
x 0
x 0 Alert Admin |
hey, novena_33, I just touched down Singapore today.. ho ho CE , CE.. sound like a history now huh.. |
| Useful To Me Not Useful To Me | |
|
novena_33
Veteran |
20-Jan-2008 12:31
|
|
x 0
x 0 Alert Admin |
with CE approval BIG should worth more....then now..... or some of the old target price...... 
|
| Useful To Me Not Useful To Me | |
|
tiptop123
Member |
20-Jan-2008 12:21
|
|
x 0
x 0 Alert Admin |
All the kateks of BIG will die hard tomorrow!!!! Just site back and watch, the BIG share price will be push real high for them to cover. Remember don't sell your share too early, let your winner run. There are indeed some big players accumulating over the past weeks for strategic reasons. It has a very high chance of hitting $3 over the next 1-2 years. Cheers! |
| Useful To Me Not Useful To Me | |
|
:idea:
Member |
20-Jan-2008 08:48
|
|
x 0
x 0 Alert Admin |
Where are the kateks?! |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
20-Jan-2008 03:52
|
|
x 0
x 0 Alert Admin |
Published January 19, 2008 Biosensors obtains CE mark for stent It will begin initial sales of flagship BioMatrix stent to Europe by April By CHEN HUIFEN HEART stent maker Biosensors International will soon be able to sell its flagship BioMatrix stent in Europe, South America and Asia, after having obtained the Conformite Europeene (CE) mark recently. The loss-making company, which announced the CE mark approval yesterday morning, said that it will begin initial sales by April, starting with Germany, Italy, Spain, the Netherlands, Switzerland and Argentina. The nod from the European regulatory authority is a milestone for the group, which is banking on the drug eluting stent (DES) with a biodegradable polymer to propel it to profitability. The announcement has also led chief financial officer Kevin Sayer to project total revenue of US$100-115 million in FY2009 ending March next year, with a gross profit margin of 55-65 per cent. About US$58-66 million of the revenue will come from DES sales. Biosensors could still post operating losses for FY2009, as it expects to incur higher expenses related to the marketing of its newly approved product. Ongoing clinical trials and consolidation costs connected with a recent acquisition in China could also shave off a fraction of its revenue. 'We believe during the last six months of the year (FY2009), we have a very good chance of reaching a breakeven point or becoming slightly profitable,' said Mr Sayer. Adding to the good news yesterday was the announcement that its licensee Terumo Corp had also received CE mark approval for the Nobori DES, based on Biosensors' technology. Under a revenue-sharing agreement inked in 2003, Biosensors will also receive payments from Terumo, which has exclusive rights to sell the Nobori stent in Japan and non-exclusive rights in the rest of the world, excluding the US. Although Nobori is likely to compete with BioMatrix in Europe, CEO Lu Yoh-Chie reckoned that the US$1.2 billion market there is huge enough for a few players. Besides, the combined efforts by both companies will be useful in garnering a bigger market share. In three years' time, Biosensors aims to capture 10 per cent of the worldwide DES market. In Asia, it plans to be more aggressive and is eyeing 25 per cent share of the US$800 million pie. In the past year, the group has been putting its foot into China, India and Indonesia through acquisitions and setting up joint ventures and subsidiaries. In China, where Biosensors has recently acquired a stent manufacturing firm, sales of BioMatrix could start in FY2010. The CE mark approval had been long in coming, amid concerns over safety issues arising from the use of first generation DES currently available in the market. Biosensors had earlier anticipated the green light to arrive in the first half of 2006. Describing the long wait as if he is having an 'overdue baby', Mr Lu added that he is 'pleased with the timing of this approval, as the increasing complexity of worldwide regulatory requirements will make it even more difficult to introduce new technologies into the marketplace'. For the first half ended September last year, Biosensors narrowed its losses to US$3.04 million, from US$15.9 million in the year-ago period. Shares of Biosensors, which were suspended yesterday, ended eight cents higher on Thursday to close at $1.04. *** Japan DES market is US$0.7B a year. Terumo will get Japan FDA approval later this year. Terumo is the largest Japanese medical device company with very extensive direct sales distribution network all over Japan. Japanese will always buy from Japanese. Plus, NOBORI (a.k.a Biomatrix) is the best clinically proven DES leader by very wide margins in all areas of trial end-point measurements. By 2010, Terumo will corner the Japan DES market with over half the Japan DES market share. Yes, Terumo will make lesser from the NOBORI DES sales because of heavy royalties payable to BIG but Terumo will pocket all the profits from their own Terumo in-house brand of balloon catheter deliver system. If they market NOBORI at US$2,500 per DES in Japan, I estimate the balloon catheter delivery system (which is sold seperately) will be sold at around US$1,000 per system. That is why BIG's licensees will still make profits even after paying heavy royalties to BIG for the DES. They make from the delivery system which is sold seperately. The regulatory approval standards has been raised higher significantly compared to the past. Future DESs will have even higher barrier of entry into the DES industry. |
| Useful To Me Not Useful To Me | |
|
bengster68
Master |
20-Jan-2008 03:05
|
|
x 0
x 0 Alert Admin |
Biomatrix is the only DES with unique biodegredable polymer (plus most effective limus family drug) and has the biggest potential to address the dreaded late-thrombosis problems founmd in all the other DESs. I give Medtronic another one more year before late-thrombosis problems start appearing in their Endeavor DES. Xience already has this problem. Durable polymers will always have these durable polymer problems. In today's Business Times article, BIG projected a 10% global DES market share in 2010 (market size of approx US$6B in 2010). BIG's 3 other licensees namely Terumo, Xtent and Devax should capture at least another 10% of global DES market share in 2010. Besides profits from BIG's own operations and JWMS, there will be royalties from these licensees (pure profits, zero cost to BIG) of around US$100m per year in 2010. I estimate in 2010, BIG should be making at least US$200m a year. This is excluding the USA market (40% of global market share). BIG is a blue chip index stock in the making. |
| Useful To Me Not Useful To Me | |
|
zhenxian
Senior |
20-Jan-2008 02:16
|
|
x 0
x 0 Alert Admin |
looks like this is going to be the few GREEN stocks on Monday le :) |
| Useful To Me Not Useful To Me | |